266 related articles for article (PubMed ID: 28239466)
21. Nivolumab-associated acute glomerulonephritis: a case report and literature review.
Jung K; Zeng X; Bilusic M
BMC Nephrol; 2016 Nov; 17(1):188. PubMed ID: 27876011
[TBL] [Abstract][Full Text] [Related]
22. Pulmonary sarcoid-like granulomatosis induced by nivolumab.
Montaudié H; Pradelli J; Passeron T; Lacour JP; Leroy S
Br J Dermatol; 2017 Apr; 176(4):1060-1063. PubMed ID: 27291635
[TBL] [Abstract][Full Text] [Related]
23. Benefit-Risk Summary of Nivolumab for Patients With Metastatic Squamous Cell Lung Cancer After Platinum-Based Chemotherapy: A Report From the US Food and Drug Administration.
Kazandjian D; Khozin S; Blumenthal G; Zhang L; Tang S; Libeg M; Kluetz P; Sridhara R; Keegan P; Pazdur R
JAMA Oncol; 2016 Jan; 2(1):118-22. PubMed ID: 26470053
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of short-term nivolumab treatment in a Chinese patient with relapsed advanced-stage lung squamous cell carcinoma: A case report.
Pi G; He H; Bi J; Li Y; Li Y; Zhang Y; Wang M; Han G; Lin C
Medicine (Baltimore); 2016 Oct; 95(40):e5077. PubMed ID: 27749580
[TBL] [Abstract][Full Text] [Related]
25. Uveitis induced by programmed cell death protein 1 inhibitor therapy with nivolumab in metastatic melanoma patient.
Kanno H; Ishida K; Yamada W; Nishida T; Takahashi N; Mochizuki K; Mizuno Y; Matsuyama K; Takahashi T; Seishima M
J Infect Chemother; 2017 Nov; 23(11):774-777. PubMed ID: 28527652
[TBL] [Abstract][Full Text] [Related]
26. Aprepitant for refractory nivolumab-induced pruritus.
Ito J; Fujimoto D; Nakamura A; Nagano T; Uehara K; Imai Y; Tomii K
Lung Cancer; 2017 Jul; 109():58-61. PubMed ID: 28577951
[TBL] [Abstract][Full Text] [Related]
27. Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma: Case report.
Chen YH; Liu FC; Hsu CH; Chian CF
Medicine (Baltimore); 2017 Jul; 96(27):e7350. PubMed ID: 28682883
[TBL] [Abstract][Full Text] [Related]
28. Vitiligo in a patient with lung adenocarcinoma treated with nivolumab: A case report.
Uenami T; Hosono Y; Ishijima M; Kanazu M; Akazawa Y; Yano Y; Mori M; Yamaguchi T; Yokota S
Lung Cancer; 2017 Jul; 109():42-44. PubMed ID: 28577948
[TBL] [Abstract][Full Text] [Related]
29. Development of psoriatic arthritis during nivolumab therapy for metastatic non-small cell lung cancer, clinical outcome analysis and review of the literature.
Ruiz-Bañobre J; Pérez-Pampín E; García-González J; Gómez-Caamaño A; Barón-Duarte FJ; López-López R; Vázquez-Rivera F
Lung Cancer; 2017 Jun; 108():217-221. PubMed ID: 28625638
[TBL] [Abstract][Full Text] [Related]
30. Severe cerebral edema following nivolumab treatment for pediatric glioblastoma: case report.
Zhu X; McDowell MM; Newman WC; Mason GE; Greene S; Tamber MS
J Neurosurg Pediatr; 2017 Feb; 19(2):249-253. PubMed ID: 27858578
[TBL] [Abstract][Full Text] [Related]
31. Recurrent dysphasia due to nivolumab-induced encephalopathy with presence of Hu autoantibody.
Raskin J; Masrori P; Cant A; Snoeckx A; Hiddinga B; Kohl S; Janssens A; Cras P; Van Meerbeeck JP
Lung Cancer; 2017 Jul; 109():74-77. PubMed ID: 28577954
[TBL] [Abstract][Full Text] [Related]
32. FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma.
Kasamon YL; de Claro RA; Wang Y; Shen YL; Farrell AT; Pazdur R
Oncologist; 2017 May; 22(5):585-591. PubMed ID: 28438889
[TBL] [Abstract][Full Text] [Related]
33. Management of toxicities of immune checkpoint inhibitors.
Spain L; Diem S; Larkin J
Cancer Treat Rev; 2016 Mar; 44():51-60. PubMed ID: 26874776
[TBL] [Abstract][Full Text] [Related]
34. Corneal graft rejection in a patient treated with nivolumab for primary lung cancer.
Le Fournis S; Gohier P; Urban T; Jeanfaivre T; Hureaux J
Lung Cancer; 2016 Dec; 102():28-29. PubMed ID: 27987584
[TBL] [Abstract][Full Text] [Related]
35. [Varied immuno-related adverse events induced by immune-check point inhibitors - Nivolumab-associated psoriasiform dermatitis related with increased serum level of interleukin-6].
Okiyama N; Tanaka R
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(2):95-101. PubMed ID: 28603207
[TBL] [Abstract][Full Text] [Related]
36. [A case of myasthenia gravis and myositis induced by nivolumab].
Konoeda F; Suzuki S; Nishimoto Y; Hoshino H; Takagi M
Rinsho Shinkeigaku; 2017 Jul; 57(7):373-377. PubMed ID: 28674287
[TBL] [Abstract][Full Text] [Related]
37. The safety of nivolumab for the treatment of advanced non-small cell lung cancer.
Metro G; Ricciuti B; Brambilla M; Baglivo S; Soli I; Minenza E; Leonardi GC; D'arpino A; Colabrese D; Tazza M; Zicari D; Minotti V; Chiari R
Expert Opin Drug Saf; 2017 Jan; 16(1):101-109. PubMed ID: 27910704
[TBL] [Abstract][Full Text] [Related]
38. Antitumor activity of nivolumab on hemodialysis after renal allograft rejection.
Ong M; Ibrahim AM; Bourassa-Blanchette S; Canil C; Fairhead T; Knoll G
J Immunother Cancer; 2016; 4():64. PubMed ID: 27777773
[TBL] [Abstract][Full Text] [Related]
39. Myxedema coma after esophagectomy.
Yuan Y; Hu Y; Xie T; Zhao Y
Ann Thorac Surg; 2010 Jul; 90(1):295-7. PubMed ID: 20609804
[TBL] [Abstract][Full Text] [Related]
40. Nivolumab for the treatment of classical Hodgkin lymphoma after failure of autologous stem cell transplant and brentuximab.
Villasboas JC; Ansell SM
Expert Rev Anticancer Ther; 2016; 16(1):5-12. PubMed ID: 26577822
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
